Celgene (CELG) Given a $128.00 Price Target at Mizuho

Mizuho set a $128.00 target price on Celgene (NASDAQ:CELG) in a research note released on Wednesday, January 17th. The firm currently has a buy rating on the biopharmaceutical company’s stock.

Several other research analysts also recently commented on the company. William Blair reiterated an outperform rating on shares of Celgene in a research note on Friday, October 20th. BidaskClub upgraded Celgene from a sell rating to a hold rating in a research note on Tuesday, December 12th. Citigroup reiterated a hold rating on shares of Celgene in a research note on Friday, December 22nd. Leerink Swann reiterated a buy rating and set a $156.00 target price on shares of Celgene in a research note on Friday, October 20th. Finally, Deutsche Bank initiated coverage on Celgene in a research note on Tuesday, December 12th. They set a hold rating and a $114.00 target price for the company. Two research analysts have rated the stock with a sell rating, thirteen have given a hold rating, seventeen have given a buy rating and two have issued a strong buy rating to the company. The company currently has an average rating of Buy and a consensus target price of $130.35.

Celgene (NASDAQ CELG) traded down $1.00 during mid-day trading on Wednesday, reaching $91.51. The company’s stock had a trading volume of 6,658,730 shares, compared to its average volume of 8,240,000. The company has a debt-to-equity ratio of 2.29, a quick ratio of 4.80 and a current ratio of 4.99. The company has a market capitalization of $68,830.00, a P/E ratio of 25.35, a price-to-earnings-growth ratio of 0.66 and a beta of 1.49. Celgene has a 12-month low of $88.32 and a 12-month high of $147.17.

Celgene (NASDAQ:CELG) last posted its quarterly earnings results on Thursday, January 25th. The biopharmaceutical company reported $1.87 earnings per share for the quarter, beating the Zacks’ consensus estimate of $1.78 by $0.09. The firm had revenue of $3.48 billion during the quarter, compared to the consensus estimate of $3.46 billion. Celgene had a return on equity of 67.50% and a net margin of 22.38%. The business’s revenue was up 16.9% compared to the same quarter last year. During the same period last year, the company earned $1.61 earnings per share. equities analysts forecast that Celgene will post 7.68 EPS for the current fiscal year.

In other Celgene news, insider Mark J. Alles purchased 3,260 shares of the stock in a transaction dated Thursday, February 8th. The stock was bought at an average price of $91.90 per share, with a total value of $299,594.00. Following the acquisition, the insider now owns 178,904 shares of the company’s stock, valued at $16,441,277.60. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 0.95% of the stock is currently owned by insiders.

Hedge funds have recently modified their holdings of the stock. Grisanti Capital Management LLC bought a new stake in shares of Celgene in the 2nd quarter valued at about $3,616,000. RiverPoint Capital Management LLC grew its position in shares of Celgene by 3.1% in the 2nd quarter. RiverPoint Capital Management LLC now owns 121,654 shares of the biopharmaceutical company’s stock valued at $15,799,000 after buying an additional 3,680 shares during the last quarter. LSV Asset Management bought a new stake in shares of Celgene in the 2nd quarter valued at about $1,701,000. Spectrum Management Group Inc. bought a new stake in shares of Celgene in the 2nd quarter valued at about $462,000. Finally, Polen Capital Management LLC grew its position in shares of Celgene by 7.7% in the 2nd quarter. Polen Capital Management LLC now owns 5,082,991 shares of the biopharmaceutical company’s stock valued at $660,128,000 after buying an additional 363,108 shares during the last quarter. Institutional investors and hedge funds own 78.10% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “Celgene (CELG) Given a $128.00 Price Target at Mizuho” was published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this news story on another website, it was stolen and republished in violation of U.S. and international trademark and copyright legislation. The legal version of this news story can be read at https://www.dispatchtribunal.com/2018/02/12/celgene-celg-stock-rating-reaffirmed-by-mizuho.html.

About Celgene

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

Analyst Recommendations for Celgene (NASDAQ:CELG)

Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply